Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.

Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Retière C, Geraghty DE, Bernard NF.

J Virol. 2019 Sep 11. pii: JVI.01185-19. doi: 10.1128/JVI.01185-19. [Epub ahead of print]

PMID:
31511383
2.

Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial.

Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.

J Virol. 2019 Aug 21. pii: JVI.02041-18. doi: 10.1128/JVI.02041-18. [Epub ahead of print]

PMID:
31434737
3.

HLA-F on Autologous HIV-Infected Cells Activates Primary NK Cells Expressing the Activating Killer Immunoglobulin-Like Receptor KIR3DS1.

Kiani Z, Bruneau J, Geraghty DE, Bernard NF.

J Virol. 2019 Aug 28;93(18). pii: e00933-19. doi: 10.1128/JVI.00933-19. Print 2019 Sep 15.

PMID:
31270222
4.

Comparison of sequence-specific oligonucleotide probe vs next generation sequencing for HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, and DPB1 typing: Toward single-pass high-resolution HLA typing in support of solid organ and hematopoietic cell transplant programs.

Smith AG, Pereira S, Jaramillo A, Stoll ST, Khan FM, Berka N, Mostafa AA, Pando MJ, Usenko CY, Bettinotti MP, Pyo CW, Nelson WC, Willis A, Askar M, Geraghty DE.

HLA. 2019 Sep;94(3):296-306. doi: 10.1111/tan.13619. Epub 2019 Jul 15.

PMID:
31237117
5.

Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis.

Geraghty DE, Thorball CW, Fellay J, Thomas R.

Front Immunol. 2019 May 9;10:970. doi: 10.3389/fimmu.2019.00970. eCollection 2019. Review.

6.

Eleven Amino Acids of HLA-DRB1 and Fifteen Amino Acids of HLA-DRB3, 4, and 5 Include Potentially Causal Residues Responsible for the Risk of Childhood Type 1 Diabetes.

Zhao LP, Papadopoulos GK, Kwok WW, Xu B, Kong M, Moustakas AK, Bondinas GP, Carlsson A, Elding-Larsson H, Ludvigsson J, Marcus C, Persson M, Samuelsson U, Wang R, Pyo CW, Nelson WC, Geraghty DE, Lernmark Å.

Diabetes. 2019 Aug;68(8):1692-1704. doi: 10.2337/db19-0273. Epub 2019 May 24.

PMID:
31127057
7.

Fetal human leukocyte antigen-C and maternal killer-cell immunoglobulin-like receptors in cases of severe preeclampsia.

Larsen TG, Hackmon R, Geraghty DE, Hviid TVF.

Placenta. 2019 Jan;75:27-33. doi: 10.1016/j.placenta.2018.11.008. Epub 2018 Nov 22.

PMID:
30712663
8.

HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1.

Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Zhang CX, Jackson E, Lisovsky I, da Fonseca S, Geraghty DE, Bernard NF.

J Immunol. 2018 Jul 1;201(1):113-123. doi: 10.4049/jimmunol.1701370. Epub 2018 May 9.

9.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

10.

Building and validating a prediction model for paediatric type 1 diabetes risk using next generation targeted sequencing of class II HLA genes.

Zhao LP, Carlsson A, Larsson HE, Forsander G, Ivarsson SA, Kockum I, Ludvigsson J, Marcus C, Persson M, Samuelsson U, Örtqvist E, Pyo CW, Bolouri H, Zhao M, Nelson WC, Geraghty DE, Lernmark Å; Better Diabetes Diagnosis (BDD) Study Group.

Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2921. Epub 2017 Sep 15. Erratum in: Diabetes Metab Res Rev. 2018 Feb;34(2):.

PMID:
28755385
11.

Different DRB1*03:01-DQB1*02:01 haplotypes confer different risk for celiac disease.

Alshiekh S, Zhao LP, Lernmark Å, Geraghty DE, Naluai ÅT, Agardh D.

HLA. 2017 Aug;90(2):95-101. doi: 10.1111/tan.13065. Epub 2017 Jun 5.

PMID:
28585303
12.

Revealing complete complex KIR haplotypes phased by long-read sequencing technology.

Roe D, Vierra-Green C, Pyo CW, Eng K, Hall R, Kuang R, Spellman S, Ranade S, Geraghty DE, Maiers M.

Genes Immun. 2017 Sep;18(3):127-134. doi: 10.1038/gene.2017.10. Epub 2017 Jun 1.

13.

Definitive class I human leukocyte antigen expression in gestational placentation: HLA-F, HLA-E, HLA-C, and HLA-G in extravillous trophoblast invasion on placentation, pregnancy, and parturition.

Hackmon R, Pinnaduwage L, Zhang J, Lye SJ, Geraghty DE, Dunk CE.

Am J Reprod Immunol. 2017 Jun;77(6). doi: 10.1111/aji.12643. Epub 2017 Feb 10.

PMID:
28185362
14.

Establishment of optimized ELISA system specific for HLA-G in body fluids.

Ouji-Sageshima N, Geraghty DE, Ishitani A, Hatake K, Ito T.

HLA. 2016 Dec;88(6):293-299. doi: 10.1111/tan.12919. Epub 2016 Oct 31.

PMID:
27797156
15.

HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1.

Burian A, Wang KL, Finton KA, Lee N, Ishitani A, Strong RK, Geraghty DE.

PLoS One. 2016 Sep 20;11(9):e0163297. doi: 10.1371/journal.pone.0163297. eCollection 2016.

16.

Distribution of HLA-G extended haplotypes and one HLA-E polymorphism in a large-scale study of mother-child dyads with and without severe preeclampsia and eclampsia.

Nilsson LL, Djurisic S, Andersen AM, Melbye M, Bjerre D, Ferrero-Miliani L, Hackmon R, Geraghty DE, Hviid TV.

HLA. 2016 Oct;88(4):172-86. doi: 10.1111/tan.12871. Epub 2016 Sep 6.

PMID:
27596021
17.

Genetic risk factors for sclerotic graft-versus-host disease.

Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Geraghty DE, Lee N, Boeckh MJ, Storer BE, Levine DM, Fan W, Zhao LP, Hansen JA.

Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.

18.

Maternal and fetal human leukocyte antigen class Ia and II alleles in severe preeclampsia and eclampsia.

Emmery J, Hachmon R, Pyo CW, Nelson WC, Geraghty DE, Andersen AM, Melbye M, Hviid TV.

Genes Immun. 2016 Jun;17(4):251-60. doi: 10.1038/gene.2016.20. Epub 2016 Apr 28.

PMID:
27121092
19.

An Object-Oriented Regression for Building Disease Predictive Models with Multiallelic HLA Genes.

Zhao LP, Bolouri H, Zhao M, Geraghty DE, Lernmark Å; Better Diabetes Diagnosis Study Group.

Genet Epidemiol. 2016 May;40(4):315-32. doi: 10.1002/gepi.21968.

20.

FCGR2C Polymorphisms Associated with HIV-1 Vaccine Protection Are Linked to Altered Gene Expression of Fc-γ Receptors in Human B Cells.

Peng X, Li SS, Gilbert PB, Geraghty DE, Katze MG.

PLoS One. 2016 Mar 25;11(3):e0152425. doi: 10.1371/journal.pone.0152425. eCollection 2016.

21.

Next-Generation Sequencing Reveals That HLA-DRB3, -DRB4, and -DRB5 May Be Associated With Islet Autoantibodies and Risk for Childhood Type 1 Diabetes.

Zhao LP, Alshiekh S, Zhao M, Carlsson A, Larsson HE, Forsander G, Ivarsson SA, Ludvigsson J, Kockum I, Marcus C, Persson M, Samuelsson U, Örtqvist E, Pyo CW, Nelson WC, Geraghty DE, Lernmark Å; Better Diabetes Diagnosis (BDD) Study Group.

Diabetes. 2016 Mar;65(3):710-8. doi: 10.2337/db15-1115. Epub 2016 Jan 6.

22.

sHLA-G and sHLA-I levels in follicular fluid are not associated with successful implantation.

Ouji-Sageshima N, Yuui K, Nakanishi M, Takeda N, Odawara Y, Yamashita M, Iwayama H, Awai K, Hashimoto H, Geraghty DE, Ishitani A, Hatake K, Ito T.

J Reprod Immunol. 2016 Feb;113:16-21. doi: 10.1016/j.jri.2015.10.001. Epub 2015 Oct 22.

PMID:
26517006
23.

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.

Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O'Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R.

Sci Transl Med. 2015 Jul 15;7(296):296ra112. doi: 10.1126/scitranslmed.aab4005.

24.

An integrated genotyping approach for HLA and other complex genetic systems.

Nelson WC, Pyo CW, Vogan D, Wang R, Pyon YS, Hennessey C, Smith A, Pereira S, Ishitani A, Geraghty DE.

Hum Immunol. 2015 Dec;76(12):928-38. doi: 10.1016/j.humimm.2015.05.001. Epub 2015 May 28.

25.

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E, Ratto-Kim S, deSouza MS, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Mullins JI, Kim JH, Rolland M.

PLoS One. 2014 Oct 28;9(10):e111334. doi: 10.1371/journal.pone.0111334. eCollection 2014.

26.

Next generation sequencing to determine HLA class II genotypes in a cohort of hematopoietic cell transplant patients and donors.

Smith AG, Pyo CW, Nelson W, Gow E, Wang R, Shen S, Sprague M, Pereira SE, Geraghty DE, Hansen JA.

Hum Immunol. 2014 Oct;75(10):1040-6. doi: 10.1016/j.humimm.2014.08.206. Epub 2014 Aug 27.

PMID:
25167774
27.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE.

J Clin Invest. 2014 Sep;124(9):3879-90. doi: 10.1172/JCI75539. Epub 2014 Aug 8.

28.

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.

J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.

29.

The essential detail: the genetics and genomics of the primate immune response.

Shen S, Pyo CW, Vu Q, Wang R, Geraghty DE.

ILAR J. 2013;54(2):181-95. doi: 10.1093/ilar/ilt043. Review.

PMID:
24174441
30.

HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors.

Goodridge JP, Burian A, Lee N, Geraghty DE.

J Immunol. 2013 Oct 1;191(7):3553-62. doi: 10.4049/jimmunol.1300081. Epub 2013 Sep 9.

31.

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.

Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.

J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.

32.

HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE.

J Immunol. 2013 Aug 15;191(4):1567-77. doi: 10.4049/jimmunol.1300080. Epub 2013 Jul 12.

33.

Recombinant structures expand and contract inter and intragenic diversification at the KIR locus.

Pyo CW, Wang R, Vu Q, Cereb N, Yang SY, Duh FM, Wolinsky S, Martin MP, Carrington M, Geraghty DE.

BMC Genomics. 2013 Feb 8;14:89. doi: 10.1186/1471-2164-14-89.

34.

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2013 Jan;27(1):238-41. doi: 10.1038/leu.2012.168. Epub 2012 Jun 22. No abstract available.

35.

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB; National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 15;203(6):773-9. doi: 10.1093/infdis/jiq125. Epub 2011 Jan 28.

36.

Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus.

Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ, Marsh SG, Miller JS, Parham P, Geraghty DE.

PLoS One. 2010 Dec 29;5(12):e15115. doi: 10.1371/journal.pone.0015115.

37.

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.

Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, López-Botet M.

Blood. 2011 Jan 20;117(3):848-56. doi: 10.1182/blood-2010-08-301374. Epub 2010 Oct 28.

38.

HLA-F is a surface marker on activated lymphocytes.

Lee N, Ishitani A, Geraghty DE.

Eur J Immunol. 2010 Aug;40(8):2308-18.

39.

HLA-F complex without peptide binds to MHC class I protein in the open conformer form.

Goodridge JP, Burian A, Lee N, Geraghty DE.

J Immunol. 2010 Jun 1;184(11):6199-208. doi: 10.4049/jimmunol.1000078. Epub 2010 May 5.

40.

Nomenclature for factors of the HLA system, 2010.

Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernández-Viña M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Müller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J.

Tissue Antigens. 2010 Apr;75(4):291-455. doi: 10.1111/j.1399-0039.2010.01466.x. Review. No abstract available.

41.

An update to HLA nomenclature, 2010.

Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Fernández-Viña M, Geraghty DE, Holdsworth R, Hurley CK, Lau M, Lee KW, Mach B, Maiers M, Mayr WR, Müller CR, Parham P, Petersdorf EW, Sasazuki T, Strominger JL, Svejgaard A, Terasaki PI, Tiercy JM, Trowsdale J.

Bone Marrow Transplant. 2010 May;45(5):846-8. doi: 10.1038/bmt.2010.79. Epub 2010 Mar 29.

PMID:
20348972
42.

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype.

Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, Maenza J, Collier AC, Geraghty DE, Smith J, Moodie Z, Mullins JI, McElrath MJ, Horton H.

J Virol. 2010 May;84(9):4461-8. doi: 10.1128/JVI.02438-09. Epub 2010 Feb 10.

43.

Resequencing of the human major histocompatibility complex in patients with rheumatoid arthritis and healthy controls in Alaska Natives of Southeast Alaska.

Yan Z, Ferucci ED, Geraghty DE, Yang Y, Lanier AP, Smith WP, Zhao LP, Hansen JA, Nelson JL.

Tissue Antigens. 2007 Dec;70(6):487-94.

PMID:
17990987
44.

Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia.

Hackmon R, Koifman A, Hyodo H, Glickman H, Sheiner E, Geraghty DE.

Am J Obstet Gynecol. 2007 Sep;197(3):255.e1-5. Erratum in: Am J Obstet Gynecol. 2008 Feb;198(2):245. Hyobo, Hirohito [corrected to Hyodo, Hironobu].

PMID:
17826409
45.

High-throughput killer cell immunoglobulin-like receptor genotyping by MALDI-TOF mass spectrometry with discovery of novel alleles.

Houtchens KA, Nichols RJ, Ladner MB, Boal HE, Sollars C, Geraghty DE, Davis LM, Parham P, Trachtenberg EA.

Immunogenetics. 2007 Jul;59(7):525-37. Epub 2007 Apr 27.

46.

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study.

Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A; AIDS Clinical Trials Group.

J Infect Dis. 2006 Oct 15;194(8):1098-107. Epub 2006 Sep 6.

PMID:
16991084
47.

Reprogramming of CTLs into natural killer-like cells in celiac disease.

Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G, Lee L, Tretiakova M, Semrad C, Kistner E, Winchester RJ, Braud V, Lanier LL, Geraghty DE, Green PH, Guandalini S, Jabri B.

J Exp Med. 2006 May 15;203(5):1343-55. Epub 2006 May 8.

48.

HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype structure and variation spanning the nonclassical class I genes.

Pyo CW, Williams LM, Moore Y, Hyodo H, Li SS, Zhao LP, Sageshima N, Ishitani A, Geraghty DE.

Immunogenetics. 2006 May;58(4):241-51. Epub 2006 Mar 29.

PMID:
16570139
49.

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.

Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, Zhao LP, McElrath MJ.

J Virol. 2006 Mar;80(5):2463-71.

50.

Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes.

Smith WP, Vu Q, Li SS, Hansen JA, Zhao LP, Geraghty DE.

Genomics. 2006 May;87(5):561-71. Epub 2006 Jan 23.

Supplemental Content

Loading ...
Support Center